Atea Pharmaceuticals (AVIR) Receivables - Other (2020)
Atea Pharmaceuticals has reported Receivables - Other over the past 1 years, most recently at $5.8 million for Q4 2020.
- Quarterly results put Receivables - Other at $5.8 million for Q4 2020, changed N/A from a year ago — trailing twelve months through Dec 2020 was $5.8 million (changed N/A YoY), and the annual figure for FY2020 was $5.8 million, changed.
- Receivables - Other for Q4 2020 was $5.8 million at Atea Pharmaceuticals.
- Over the last five years, Receivables - Other for AVIR hit a ceiling of $5.8 million in Q4 2020 and a floor of $5.8 million in Q4 2020.